EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer

Oncogene

Volumn 29, Issue 34, 2010, Pages 4741-4751

  Singh, A ^a   Settleman, J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cancer; cancer stem cells; drug resistance; EMT

Indexed keywords

MICRORNA; RNA; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER STEM CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL RENEWAL; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG RESISTANCE; EPITHELIUM CELL; MESODERM; NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; MESODERM; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 77956178360     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.215     Document Type: Review

References (102)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ,Clarke MF. (2003). Prospective identification of tumorigenic breastcancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
2. Ashburner BP, Westerheide SD, Baldwin Jr. S. (2001). The p65 (RelA)subunit of NF-kappaB interacts with the histone deacetylase(HDAC) corepressors HDAC1 and HDAC2 to negatively regulategene expression. Mol Cell Biol 21: 7065-7077.
3. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I et al. (2009).Senescence impairs successful reprogramming to pluripotent stemcells. Genes Dev 23: 2134-2139.
4. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al.(2009). SOX2 is an amplified lineage-survival oncogene in lung andesophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
5. Baulcombe DC. (2006). Short silencing RNA: the dark matter ofgenetics? Cold Spring Harb Symp Quant Biol 71: 13-20.
6. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev Aet al. (2008). An embryonic stem cell-like gene expression signaturein poorly differentiated aggressive human tumors. Nat Genet 40:499-507.
7. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia isorganized as a hierarchy that originates from a primitive hematopoieticcell. Nat Med 3: 730-737.
8. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna Set al. (2008). A reciprocal repression between ZEB1 and members ofthe miR-200 family promotes EMT and invasion in cancer cells.EMBO Rep 9: 582-589.
9. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al.(2007). The triple negative paradox: primary tumor chemosensitivityof breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
10. Chng Z, Teo A, Pedersen RA, Vallier L. (2010). SIP1 mediates cell-fatedecisions between neuroectoderm and mesendoderm in humanpluripotent stem cells. Cell Stem Cell 6: 59-70.
11. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L,Bruyneel E et al. (2001). The two-handed E box binding zinc fingerprotein SIP1 downregulates E-cadherin and induces invasion. MolCell 7: 1267-1278.
12. Conery AR, Cao Y, Thompson EA, Townsend Jr. M, Ko TC, Luo K.(2004). Akt interacts directly with Smad3 to regulate the sensitivityto TGF-beta induced apoptosis. Nat Cell Biol 6: 366-372.
13. Davis BN, Hilyard AC, Lagna G, Hata A. (2008). SMAD proteins controlDROSHA-mediated microRNA maturation. Nature 454: 56-61.
14. Deonarain MP, Kousparou CA, Epenetos AA. (2009). Antibodiestargeting cancer stem cells: a new paradigm in immunotherapy?MAbs 1: 12-25.
15. Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling intumor suppression and cancer progression. Nat Genet 29: 117-129.
16. Dubrovska A, Kim S, Salamone RJ, Walker Jr., Maira SM, Garcia-Echeverria C et al. (2009). The role of PTEN/Akt/PI3K signaling inthe maintenance and viability of prostate cancer stem-like cellpopulations. Proc Natl Acad Sci USA 106: 268-273.
17. Dvorak HF. (1986). Tumors: wounds that do not heal. Similaritiesbetween tumor stroma generation and wound healing. N EnglJ Med 315: 1650-1659.
18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, ParkJO et al. (2007). MET amplification leads to gefitinib resistance inlung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
19. Feuring-Buske M, Hogge DE. (2001). Hoechst 33342 efflux identifiesa subpopulation of cytogenetically normal CD34(\+)CD38(-)progenitor cells from patients with acute myeloid leukemia. Blood97: 3882-3889.
20. Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A.(2008). Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT andinhibition of growth arrest and apoptosis. Oncogene 27: 1218-1230.
21. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, GoodallGJ et al. (2009). Contextual extracellular cues promote tumor cellEMT and metastasis by regulating miR-200 family expression.Genes Dev 23: 2140-2151.
22. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J,Brown M et al. (2007). ALDH1 is a marker of normal andmalignant human mammary stem cells and a predictor of poorclinical outcome. Cell Stem Cell 1: 555-567.
23. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid Get al. (2008). The miR-200 family and miR-205 regulate epithelial tomesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol10: 593-601.
24. Gupta PB, Chaffer CL, Weinberg RA. (2009a). Cancer stem cells:mirage or reality? Nat Med 15: 1010-1012.
25. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RAet al. (2009b). Identification of selective inhibitors of cancer stemcells by high-throughput screening. Cell 138: 645-659.
26. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP,Manova-Todorova K, Holland EC. (2008). PI3K pathway regulatessurvival of cancer stem cells residing in the perivascular niche followingradiation in medulloblastoma in vivo. Genes Dev 22: 436-448.
27. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D,Goodson S et al. (2005). A microRNA polycistron as a potentialhuman oncogene. Nature 435: 828-833.
28. Heldin CH, Landstrom M, Moustakas A. (2009). Mechanism of TGFbetasignaling to growth arrest, apoptosis, and epithelial- mesenchymaltransition. Curr Opin Cell Biol 21: 166-176.
29. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba Met al. (2007). Distinct populations of cancer stem cells determinetumor growth and metastatic activity in human pancreatic cancer.Cell Stem Cell 1: 313-323.
30. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. (2009). Metforminselectively targets cancer stem cells, and acts together withchemotherapy to block tumor growth and prolong remission.Cancer Res 69: 7507-7511.
31. Huber MA, Kraut N, Beug H. (2005). Molecular requirements forepithelial-mesenchymal transition during tumor progression. CurrOpin Cell Biol 17: 548-558.
32. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH et al.(2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
33. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I et al. (2009).TGF-beta activates Akt kinase through a microRNA-dependentamplifying circuit targeting PTEN. Nat Cell Biol 11: 881-889.
34. Keniry M, Parsons R. (2008). The role of PTEN signaling perturbationsin cancer and in targeted therapy. Oncogene 27: 5477-5485.
35. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS et al.(2008). MicroRNA-155 is regulated by the transforming growthfactor beta/Smad pathway and contributes to epithelial cellplasticity by targeting RhoA. Mol Cell Biol 28: 6773-6784.
36. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. (2006). Histonedeacetylase inhibitors induce VHL and ubiquitin-independentproteasomal degradation of hypoxia-inducible factor 1alpha. MolCell Biol 26: 2019-2028.
37. Korpal M, Lee ES, Hu G, Kang Y. (2008). The miR-200 familyinhibits epithelial-mesenchymal transition and cancer cell migrationby direct targeting of E-cadherin transcriptional repressors ZEB1and ZEB2. J Biol Chem 283: 14910-14914.
38. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, MontgomeryCL, Hwang HW et al. (2009). Therapeutic microRNA deliverysuppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017.
39. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al.(2006). Transformation from committed progenitor to leukaemiastem cell initiated by MLL-AF9. Nature 442: 818-822.
40. Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, Fricker Get al. (2009). Potent and selective inhibitors of breast cancerresistance protein (ABCG2) derived from the p-glycoprotein(ABCB1) modulator tariquidar. J Med Chem 52: 1190-1197.
41. LaGamba D, Nawshad A, Hay ED. (2005). Microarray analysis ofgene expression during epithelial-mesenchymal transformation. DevDyn 234: 132-142.
42. Lane AA, Chabner BA. (2009). Histone deacetylase inhibitors incancer therapy. J Clin Oncol 27: 5459-5468.
43. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T,Caceres-Cortes J et al. (1994). A cell initiating human acute myeloidleukaemia after transplantation into SCID mice. Nature 367:645-648.
44. Leder A, Orkin S, Leder P. (1975). Differentiation of erythroleukemiccells in the presence of inhibitors of DNA synthesis. Science 190:893-894.
45. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M et al.(2009a). The Ink4/Arf locus is a barrier for iPS cell reprogramming.Nature 460: 1136-1139.
46. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al.(2008). Intrinsic resistance of tumorigenic breast cancer cells tochemotherapy. J Natl Cancer Inst 100: 672-679.
47. Li Y, VandenBoom II TG, Kong D, Wang Z, Ali S, Philip PA et al.(2009b). Up-regulation of miR-200 and let-7 by natural agents leadsto the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712.
48. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al.(2008). Response to neoadjuvant therapy and long-term survivalin patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281.
49. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009).Aberrant luminal progenitors as the candidate target population forbasal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913.
50. Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jenson ABet al. (2009). Mouse fibroblasts lacking RB1 function form spheresand undergo reprogramming to a cancer stem cell phenotype. CellStem Cell 4: 336-347.
51. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. (2007).Transgenic over-expression of the microRNA miR-17-92 clusterpromotes proliferation and inhibits differentiation of lung epithelialprogenitor cells. Dev Biol 310: 442-453.
52. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, ChambonP et al. (2008). Cutaneous cancer stem cell maintenance is dependenton beta-catenin signalling. Nature 452: 650-653.
53. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al.(2008). The epithelial-mesenchymal transition generates cells withproperties of stem cells. Cell 133: 704-715.
54. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B,Falzon M et al. (2010). Progressive 3q amplification consistentlytargets SOX2 in preinvasive squamous lung cancer. Am J RespirCrit Care Med (e-pub ahead of print 18 March 2010
55. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al.(2004). PTEN activation contributes to tumor inhibition bytrastuzumab, and loss of PTEN predicts trastuzumab resistance inpatients. Cancer Cell 6: 117-127.
56. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al.(2006). A collection of breast cancer cell lines for the study offunctionally distinct cancer subtypes. Cancer Cell 10: 515-527.
57. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human coloncancer cell capable of initiating tumour growth in immunodeficientmice. Nature 445: 106-110.
58. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. (2006). Geneexpression and benefit of chemotherapy in women with nodenegative,estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734.
59. Pardal R, Clarke MF, Morrison SJ. (2003). Applying the principles ofstem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
60. Park SM, Gaur AB, Lengyel E, Peter ME. (2008). The miR-200family determines the epithelial phenotype of cancer cells bytargeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev22: 894-907.
61. Peacock CD, Watkins DN. (2008). Cancer stem cells and the ontogenyof lung cancer. J Clin Oncol 26: 2883-2889.
62. Peinado H, Olmeda D, Cano A. (2007). Snail, Zeb and bHLH factorsin tumour progression: an alliance against the epithelial phenotype?Nat Rev Cancer 7: 415-428.
63. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, deMartino I et al. (2008). E2F1-regulated microRNAs impairTGFbeta-dependent cell-cycle arrest and apoptosis in gastriccancer. Cancer Cell 13: 272-286.
64. Polyak K, Weinberg RA. (2009). Transitions between epithelial andmesenchymal states: acquisition of malignant and stem cell traits.Nat Rev Cancer 9: 265-273.
65. Postigo AA, Depp JL, Taylor JJ, Kroll KL. (2003). Regulation ofSmad signaling through a differential recruitment of coactivatorsand corepressors by ZEB proteins. EMBO J 22: 2453-2462.
66. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM,Morrison SJ. (2008). Efficient tumour formation by single humanmelanoma cells. Nature 456: 593-598.
67. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC,Rougvie AE et al. (2000). The 21-nucleotide let-7 RNA regulatesdevelopmental timing in Caenorhabditis elegans. Nature 403:901-906.
68. Remy I, Montmarquette A, Michnick SW. (2004). PKB/Aktmodulates TGF-beta signalling through a direct interaction withSmad3. Nat Cell Biol 6: 358-365.
69. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M,Peschle C et al. (2007). Identification and expansion of humancolon-cancer-initiating cells. Nature 445: 111-115.
70. Riggs MG, Whittaker RG, Neumann Jr., Ingram VM. (1977). n-Butyrate causes histone modification in HeLa and Friend erythroleukaemiacells. Nature 268: 462-464.
71. Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, AmbudkarSV et al. (2007). Inhibition of ABCG2-mediated transport byprotein kinase inhibitors with a bisindolylmaleimide or indolocarbazolestructure. Mol Cancer Ther 6: 1877-1885.
72. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A,Kalli KR et al. (2009). Immune-induced epithelial to mesenchymaltransition in vivo generates breast cancer stem cells. Cancer Res 69:2887-2895.
73. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T et al.(2009). SIP1 protein protects cells from DNA damage-inducedapoptosis and has independent prognostic value in bladder cancer.Proc Natl Acad Sci USA 106: 14884-14889.
74. Seoane J, Le HV, Shen L, Anderson SA, Massague J. (2004).Integration of Smad and forkhead pathways in the controlof neuroepithelial and glioblastoma cell proliferation. Cell 117:211-223.
75. Sharma SV, Bell DW, Settleman J, Haber DA. (2007). Epidermalgrowth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
76. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran Set al. (2010). A chromatin-mediated reversible drug-tolerant state incancer cell subpopulations. Cell 141: 69-80.
77. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. (2007). Molecular definition of breast tumorheterogeneity. Cancer Cell 11: 259-273.
78. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy Net al. (2009). A gene expression signature associated with 'K-Rasaddiction' reveals regulators of EMT and tumor cell survival.Cancer Cell 15: 489-500.
79. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al.(2004). Identification of human brain tumour initiating cells. Nature432: 396-401.
80. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al.(2001). Gene expression patterns of breast carcinomas distinguishtumor subclasses with clinical implications. Proc Natl Acad Sci USA98: 10869-10874.
81. Takahashi K, Yamanaka S. (2006). Induction of pluripotent stem cellsfrom mouse embryonic and adult fibroblast cultures by definedfactors. Cell 126: 663-676.
82. Thiery JP. (2003). Epithelial-mesenchymal transitions in developmentand pathologies. Curr Opin Cell Biol 15: 740-746.
83. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelialmesenchymaltransitions in development and disease. Cell 139:871-890.
84. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH,Moustakas A. (2006). Transforming growth factor-beta employsHMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175-183.
85. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RMet al. (2009). Immortalization eliminates a roadblock during cellularreprogramming into iPS cells. Nature 460: 1145-1148.
86. Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS,Tylzanowski P et al. (1999). SIP1, a novel zinc finger/homeodomainrepressor, interacts with Smad proteins and binds to 50-CACCTsequences in candidate target genes. J Biol Chem 274: 20489-20498.
87. Voulgari A, Pintzas A. (2009). Epithelial-mesenchymal transition incancer metastasis: mechanisms, markers and strategies to overcomedrug resistance in the clinic. Biochim Biophys Acta 1796: 75-90.
88. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH et al.(2008). Transforming growth factor beta engages TACE and ErbB3to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressingbreast cancer and desensitizes cells to trastuzumab. Mol CellBiol 28: 5605-5620.
89. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag Aet al. (2009). The EMT-activator ZEB1 promotes tumorigenicityby repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487-1495.
90. Wendt MK, Allington TM, Schiemann WP. (2009). Mechanisms of theepithelial-mesenchymal transition by TGF-beta. Future Oncol 5:1145-1168.
91. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al.(1999). Expression of CD44 in Apc and Tcf mutant mice impliesregulation by the WNT pathway. Am J Pathol 154: 515-523.
92. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, RavdelL et al. (2006). Restoring E-cadherin expression increases sensitivityto epidermal growth factor receptor inhibitors in lung cancer celllines. Cancer Res 66: 944-950.
93. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al.(2009). EpCAM-positive hepatocellular carcinoma cells are tumorinitiatingcells with stem/progenitor cell features. Gastroenterology136: 1012-1024.
94. Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition:at the crossroads of development and tumor metastasis. Dev Cell 14:818-829.
95. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L et al.(2005). Epithelial versus mesenchymal phenotype determines in vitrosensitivity and predicts clinical activity of erlotinib in lung cancerpatients. Clin Cancer Res 11: 8686-8698.
96. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu Het al. (2006). Pten dependence distinguishes haematopoietic stemcells from leukaemia-initiating cells. Nature 441: 475-482.
97. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. (2007a). let-7regulates self renewal and tumorigenicity of breast cancer cells. Cell131: 1109-1123.
98. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, FraneJL, Tian S et al. (2007b). Induced pluripotent stem cell lines derivedfrom human somatic cells. Science 318: 1917-1920.
99. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM et al.(2010). Sex determining region Y-Box 2 (SOX2) is a potential celllineagegene highly expressed in the pathogenesis of squamous cellcarcinomas of the lung. PLoS One 5: e9112.
100. Zeisberg M, Neilson EG. (2009). Biomarkers for epithelial- mesenchymaltransitions. J Clin Invest 119: 1429-1437.
101. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB.(2009). Tumour-initiating cells: challenges and opportunities foranticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
102. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J et al. (2007).Activation of the PTEN/mTOR/STAT3 pathway in breast cancerstem-like cells is required for viability and maintenance. Proc NatlAcad Sci USA 104: 16158-16163.